Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2011 11:53 ET | Source: Cutting Edge Information

Drug Companies Spend an Average $13,000 per Patient on Comparative Effectiveness Research in Phase IV

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 9, 2011) - The cost of running a comparative effectiveness trial is $13,087 per patient during Phase IV, according to a study by Cutting Edge...
August 04, 2011 10:50 ET | Source: Cutting Edge Information

Flat Fee Most Common Key Opinion Leader Compensation Method in Europe

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 4, 2011) - As scrutiny over key opinion leader (KOL) payments intensifies in Europe, life sciences companies set fee schedules and establish protocol...
August 04, 2011 10:19 ET | Source: Cutting Edge Information

Pricing Activities Approach $1 Million Budget to Support Innovative Pharmaceutical Products

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 4, 2011) - The cost to set a price on an innovative drug is nearly $1 million, according to a new study by Cutting Edge Information. Compared to...
August 03, 2011 09:12 ET | Source: Cutting Edge Information

54% of Drug Companies Pursue In-Licensing Deals to Accelerate Development Timelines

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 3, 2011) - New data show that 54% of drug companies sign in-licensing deals to accelerate development timelines, according to Cutting Edge...
August 02, 2011 10:12 ET | Source: Cutting Edge Information

51% of Pharmaceutical Companies Outsource Part or All of Medical Communications

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 2, 2011) - Global medical affairs departments outsource more activities than U.S. or other country-level groups, according to a new study from Cutting...
August 02, 2011 09:11 ET | Source: Cutting Edge Information

Defensive Pricing and Patent Litigation Are Favored Counter-Generics Strategies, for Now

RESEARCH TRIANGLE PARK, NC--(Marketwire - Aug 2, 2011) - Short-term strategies, such as patent litigation and defensive pricing, have been the most popular counter-generics tactics for...
July 27, 2011 12:05 ET | Source: Cutting Edge Information

Phase IV Clinical Trial Teams Identify Top Challenges for Post-Marketing Studies

PHILADELPHIA, PA and RESEARCH TRIANGLE PARK, NC--(Marketwire - Jul 27, 2011) - Phase IV clinical trial managers face several challenges in maximizing the impact of post-marketing studies, but...
July 27, 2011 08:59 ET | Source: Cutting Edge Information

Next-Generation Pharma Reps Add Reimbursement and Managed Care Support to Arsenal

RESEARCH TRIANGLE PARK, NC--(Marketwire - Jul 27, 2011) - Savvy pharmaceutical companies have increased prescription volume by holding on to drug reps who provide health economics expertise and...
July 26, 2011 09:12 ET | Source: Cutting Edge Information

Small Drug Companies Increase Health Economics Spending 55%

PHILADELPHIA, PA--(Marketwire - Jul 26, 2011) - A study of health economics and outcomes research (HEOR) groups across the life science industry finds that small companies increased their spending...
July 21, 2011 12:06 ET | Source: Cutting Edge Information

Hard Limits on Thought Leader Compensation Employed Less Often by Pharma

RESEARCH TRIANGLE PARK, NC and BOSTON, MA--(Marketwire - Jul 21, 2011) - As compliance and medical affairs teams prepare for the Sunshine Act, they are relying less on exact compensation limits for...